Fx-1006A + Placebo
Phase 2/3Completed 0 watching 0 views this week📈 Rising
64
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Familial Amyloid Polyneuropathy
Conditions
Familial Amyloid Polyneuropathy
Trial Timeline
Jan 1, 2007 → May 1, 2009
NCT ID
NCT00409175About Fx-1006A + Placebo
Fx-1006A + Placebo is a phase 2/3 stage product being developed by Pfizer for Familial Amyloid Polyneuropathy. The current trial status is completed. This product is registered under clinical trial identifier NCT00409175. Target conditions include Familial Amyloid Polyneuropathy.
Hype Score Breakdown
Clinical
22
Activity
15
Company
9
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00409175 | Phase 2/3 | Completed |
Competing Products
20 competing products in Familial Amyloid Polyneuropathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Bromocriptine Mesilate + Placebos | Towa Pharmaceutical | Phase 1/2 | 40 |
| SHR-1209 | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| SHR-1209 ;placebo + SHR-1209 ;placebo + SHR-1209 ;placebo | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Rosuvastatin 20mg + Placebo | AstraZeneca | Phase 3 | 77 |
| rosuvastatin calcium + rosuvastatin calcium + rosuvastatin calcium | AstraZeneca | Phase 3 | 77 |
| Rosuvastatin + Placebo | AstraZeneca | Phase 3 | 77 |
| Rosuvastatin 20mg | AstraZeneca | Phase 3 | 77 |
| AZD0780 + Placebo | AstraZeneca | Phase 3 | 77 |
| Anacetrapib + Placebo for anacetrapib | Merck | Phase 3 | 77 |
| Statins and Ezetimibe | Merck | Pre-clinical | 23 |
| Comparator: niacin (+) laropiprant (MK0524A) + Comparator: placebo | Merck | Phase 3 | 77 |
| MK-0524A + MK-0524A | Merck | Phase 1 | 33 |
| Enlicitide Decanoate + Placebo | Merck | Phase 2/3 | 65 |
| Inclisiran + Placebo | Novartis | Phase 3 | 77 |
| DFV890 | Novartis | Phase 2 | 52 |
| Canakinumab | Novartis | Phase 2 | 52 |
| Inclisiran Sodium for injection + Placebo + Placebos | Novartis | Phase 3 | 77 |
| LCQ908 + Placebo | Novartis | Phase 3 | 77 |
| Inclisiran | Novartis | Phase 3 | 77 |
| Inclisiran + Placebo | Novartis | Phase 3 | 77 |